Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD70-CAR-T cells |
Synonyms | |
Therapy Description |
CD70-CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD70, which may increase antitumor immune response and inhibit tumor growth (PMID: 34323938). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD70-CAR-T cells | CD70 CAR T-cells|anti-CD70 CAR-expressing T lymphocytes | CD70-CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD70, which may increase antitumor immune response and inhibit tumor growth (PMID: 34323938). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06326463 | Phase I | CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT06345027 | Phase I | CD70-CAR-T cells | CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (CASEY) | Not yet recruiting | USA | 0 |